NuCana plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NuCana plc (NCNA) operates as a clinical-stage biopharmaceutical company focused on developing cancer treatments using its proprietary ProTide phosphoramidate technology platform, which transforms nucleoside analogs and chemotherapy agents into more effective anti-cancer medicines by overcoming resistance mechanisms and enhancing metabolite concentrations in tumor cells. The company advances a pipeline of product candidates including NUC-7738, a CD73 inhibitor in Phase 2 trials for advanced solid tumors often combined with immunotherapy agents like pembrolizumab; NUC-3373, a ProTide transformation of 5-fluorouracil targeted at colorectal and other cancers; and Acelarin (NUC-1022), a ProTide form of gemcitabine studied in ovarian and biliary tract cancers. NuCana conducts research and clinical development activities across these oncology segments, targeting patients with solid tumors and hematologic malignancies. Founded in 1997 and headquartered in Edinburgh, Scotland, with a U.S. office in Newton, Massachusetts, NuCana maintains operations primarily in the United Kingdom and United States. The company serves global oncology markets through its clinical programs and engages pharmaceutical partners for combination therapies. Recent developments include a $7 million registered direct offering in May 2025 to fund pipeline advancement; entry into a $100 million American Depositary Shares sales agreement with A.G.P./Alliance Global Partners and Laidlaw & Company in June 2025 for flexible capital access; raising an additional £19 million via at-the-market program in July 2025 followed by cancellation of all remaining Series A Warrants from the prior financing; release of encouraging Phase 2 data for NUC-7738 and NUC-3373 in 2025 with initial expansion study results for NUC-7738 expected in Q4 2025; achievement of Nasdaq continued listing compliance; and extension of cash runway into 2029 supported by £2.7 million in other income during Q3 2025.
NuCana Appoints Ian Webster as Chief Financial Officer
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana Compliant with All Nasdaq Continued Listing Criteria
NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
NuCana Announces ADS Ratio Change
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
NuCana Announces Plan to Implement ADS Ratio Change
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
Baillie Gifford's Strategic Acquisition of NuCana PLC Shares
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States